Educational content from recorded physician discussions — not medical advice. Always talk to your child's care team about your child's situation.
Content of this collection
Esophageal Atresia & Tracheoesophageal Fistula (EA/TEF) Types Explained for Pediatric Surgery
Watch →
This video provides a clear, visual explanation of Esophageal Atresia (EA) and Tracheoesophageal Fistula (TEF), common congenital anomalies in pediatric surgery. Jill Knepprath, MD demonstrates normal anatomy and then breaks down the differ
video2:11 · Sep 2026
Effect of Timing of Secondary Alveolar Bone Grafting on Maxillary Incisor Development in Patients With Cleft Lip and Palate
Watch →
This video, featuring Lizzy Lee, PA-C from Cincinnati Children's, discusses a study on the effect of secondary alveolar bone grafting (sABG) timing on maxillary incisor development in cleft lip and palate patients. The research found no sig
video0:42 · Sep 2026
Long-term obstetric and gynecologic care for patients with anorectal malformations
Listen →
Long-term obstetric and gynecologic care for patients with anorectal malformationsThis article from the Journal of Pediatric Surgery provides clinical guidelines for the long-term obstetric and gynecologic care of indivi
podcast21:04 · Sep 2026
Featured picks for families are being prepared — the summaries above are written for you.
Expert statements from the recordings in this collection.
Long-term obstetric and gynecologic care for patients with anorectal malformations
A 2026 study published in the Journal of Pediatric Surgery examines the lifelong obstetric and gynecologic care required for individuals born with anorectal malformations.
Adult medical guidelines are written for standard anatomy and cannot be safely applied to patients with anorectal malformations 20 or 30 years after childhood surgery without accounting for their specific surgical history.
Many patients with anorectal malformations present with varying uterine anomalies, introducing mechanical and safety unknowns for standard IUD placement.
Standard IUDs rely on predictable uterine cavity geometry to sit securely and provide effective coverage; in atypical cavities (unicornuate or septate uterus), data on unintended pregnancy risks is remarkably sparse.
Providers sometimes physically alter the IUD prior to insertion, such as removing one of the inert arms, to accommodate the unique dimensions of the patient's uterus.
Safe IUD placement in patients with uterine anomalies often requires continuous ultrasound guidance and in many instances necessitates placement under anesthesia utilizing hysteroscopy to visually confirm the device is not piercing the uterine wall.
Patients with anorectal malformations frequently present with systemic comorbidities including concomitant renal anomalies or cardiac structural issues, which directly interfere with hormonal contraceptive safety profiles.
For patients managing chronic kidney disease (nephrotic syndrome or active dialysis), combined hormonal contraception (estrogen and progesterone) drastically increases the risk of thromboembolic events and is classified as Category 4, representing an unacceptable health risk.
Patients with renal anomalies often battle hyperkalemia (elevated potassium levels), making progesterone-only pills containing drospirenone strictly contraindicated because drospirenone is potassium-sparing and risks severe, potentially fatal hyperkalemia and cardiac arrhythmias.
If a patient's anatomical map means they do not possess a cervix, the standard Pap smear screening protocol is physically impossible, but HPV-related diseases can still occur in surrounding mucosal tissues of the vaginal canal and vulva.
For patients without a cervix, surveillance protocol shifts from cytological swabbing to meticulous periodic visual inspection of the lower genital tract.
HPV vaccination remains critical for patients with anorectal malformations, if not more so, given the complexities of treating mucosal dysplasia in altered anatomy.
Native vaginal tissue in patients with anorectal malformations possesses incredible elastic capacity; tissue that appears shortened at rest can stretch smoothly to accommodate full depth with only slight pressure.
Native vaginal tissue elasticity in altered anatomical environments requires dedicated mechanical upkeep; patients typically incorporate vaginal dilators or engage in regular penile-vaginal coitus several times a week to preserve functional length and elasticity over decades.
For patients managing anatomic shortening or dyspareunia, providers frequently recommend penile rings as a physical buffer to limit penetration depth, preventing deep impact against a surgically blind-ended vaginal vault.
Providers use targeted vibration to desensitize the introitus and help relax surrounding pelvic floor musculature in patients with dyspareunia.
There is zero clinical data regarding the safety, friction coefficients, or toxic shock risks of using standard intravaginal products (tampons, menstrual cups, discs, pessaries) inside a graft neovagina.
Graft tissue, regardless of where it is relocated in the human body, remains highly susceptible to the specific diseases of its original tissue lineage; relocating tissue does not rewrite its cellular DNA or immunological profile.
If a surgeon utilizes a section of colon to construct a neovagina, that tissue functionally remains colonic mucosa, and a patient could develop inflammatory bowel disease or colitis entirely contained within their neovagina.
If a neovagina is constructed using a skin graft, that internal tissue remains vulnerable to dermatological conditions including squamous cell carcinoma or melanoma.
For bowel graft neovaginas, long-term surveillance must include screening for colorectal cancer directly within the neovaginal canal.
A bowel neovagina represents a strict contraindication for vaginal delivery because bowel tissue lacks the elastin fibers and rugae designed for massive temporary distention to accommodate a fetal head, carrying an astronomical risk of catastrophic tissue rupture.
Females with graft neovaginas who also lack a functional uterus are not candidates for uterine transplants according to current medical guidelines, as the foundational vascular and structural support required cannot be anchored safely to a graft neovagina.
A history of multiple complex pelvic surgeries during childhood inevitably results in dense pelvic adhesions and scar tissue throughout the pelvic cavity, often altering the natural motility of the fallopian tubes and dramatically elevating the risk of ectopic pregnancy.
Patients with anorectal malformations and uterine anomalies (diminished uterine volume, structural septums) face significantly higher rates of early pregnancy loss and preterm labor.
Obstetric surveillance protocol for ARM patients includes high-frequency serial ultrasounds and continuous monitoring of cervical length to detect preterm dilation before it becomes irreversible.
If a patient has undergone a prior bladder augmentation, they will experience a false positive urine pregnancy test up to 75% of the time.
Bladder augmentation frequently uses a segment of the patient's own intestine (ileum or colon) to enlarge bladder capacity; this intestinal tissue continues to secrete intestinal mucus and specific glycoproteins directly into the urine.
The glycoproteins secreted by intestinal tissue in an augmented bladder chemically cross-react with the antibodies utilized in standard over-the-counter urine HCG assays, causing false positive results.
Pregnancy in patients with bladder augmentation must be confirmed via serum beta-HCG blood test, bypassing the urinary tract entirely.